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Cerebral regional tissue Oxygen Saturation
to Guide Oxygen Delivery in preterm
neonates during immediate transition after
birth (COSGOD III): an investigator-initiated,
randomized, multi-center, multi-national,
clinical trial on additional cerebral tissue
oxygen saturation monitoring combined
with defined treatment guidelines versus
standard monitoring and treatment as
usual in premature infants during
immediate transition: study protocol for a
randomized controlled trial
Gerhard Pichler1* , Sigrid Baumgartner2, Marlene Biermayr3, Eugene Dempsey4, Hans Fuchs5, Tom G. Goos6,7,
Gianluca Lista8, Laila Lorenz9, Lukasz Karpinski10, Souvik Mitra11, Lilijana Kornhauser-Cerar12, Alexander Avian13,
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Abstract
Background: Transition immediately after birth is a complex physiological process. The neonate has to establish
sufficient ventilation to ensure significant changes from intra-uterine to extra-uterine circulation. If hypoxia or
bradycardia or both occur, as commonly happens during immediate transition in preterm neonates, cerebral
hypoxia–ischemia may cause perinatal brain injury.
The primary objective of the COSGOD phase III trial is to investigate whether it is possible to increase survival
without cerebral injury in preterm neonates of less than 32 weeks of gestation by targeting cerebral tissue oxygen
saturation (crSO2) using specified clinical treatment guidelines during the immediate transition period after birth
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(the first 15 min) in addition to the routine monitoring of arterial oxygen saturation (SpO2) and heart rate (HR).
Methods/Design: COSGOD III is an investigator-initiated, randomized, multi-center, multi-national, phase III clinical
trial. Inclusion criteria are neonates of less than 32 weeks of gestation, decision to provide full life support, and
parental informed consent. Exclusion criteria are severe congenital malformations of brain, heart, lung, or prenatal
cerebral injury or a combination of these.
The premature infants will be randomly assigned to study or control groups. Both groups will have a near-infrared
spectroscopy (NIRS) device (left frontal), pulse oximeter (right palm/wrist), and electrocardiogram placed immediately
after birth. In the study group, the crSO2, SpO2, and HR readings are visible, and the infant will receive treatment in
accordance with defined treatment guidelines. In the control group, only SpO2 and HR will be visible, and the infant
will receive routine treatment. The intervention period will last for the first 15min after birth during the immediate
transition period and resuscitation. Thereafter, each neonate will be followed up for primary outcome to term date or
discharge. The primary outcome is mortality or cerebral injury (or both) defined as any intra-ventricular bleeding or
cystic periventricular leukomalacia (or both). Secondary outcomes are neonatal morbidities.
Discussion: crSO2 monitoring during immediate transition has been proven to be feasible and improve cerebral
oxygenation during immediate transition. The additional monitoring of crSO2 with dedicated interventions may
improve outcome of preterm neonates as evidenced by increased survival without cerebral injury.
Trial registration: ClinicalTrials.gov Identifier: NCT03166722. Registered March 5, 2017.
Keywords: Neonate, Cerebral oxygenation, Immediate transition, Cerebral injury, Mortality
Background
The transition from the intra-uterine to extra-uterine
environment is a complex physiological process charac-
terized by major physiological changes in respiratory and
hemodynamic functions, which are predominantly initi-
ated by breathing at birth and clamping of the umbilical
cord [1]. If hypoxia or bradycardia or both occur, as
commonly happens during immediate transition in pre-
term neonates, cerebral hypoxia–ischemia may cause
perinatal brain injury [2–4]. Therefore, protecting the
brain from injury is of major importance since up to
10% of infants who survive very preterm birth will de-
velop motor deficits such as cerebral palsy [3] and cogni-
tive deficits [5].
Monitoring during immediate transition after birth
Routine non-invasive monitoring during immediate
transition after birth might include arterial oxygen
saturation (SpO2) and heart rate (HR) measurement
with pulse oximetry/electrocardiogram (ECG), blood
pressure, and temperature measurements. Special
interest has grown in the use of pulse oximetry and
ECG to monitor SpO2 and HR during this transitional
period [6–10].
However, there is an ongoing debate about the use of
supplemental oxygen during neonatal resuscitation. It is
still unknown which oxygen concentration is appropriate
for preterm infants during immediate transition after
birth [10]. In addition, non-invasive monitoring of SpO2
does not provide information about adequate oxygen
supply to the brain.
Recently, there has been increasing interest in continu-
ous monitoring of cerebral tissue oxygen saturation
(crSO2) using near-infrared spectroscopy (NIRS) during
immediate fetal-to-neonatal transition [2, 11]. In 1992,
Peebles et al. reported the first study of NIRS during im-
mediate transition in term neonates and showed a rapid
increase of oxygenated hemoglobin and decrease of deox-
ygenated hemoglobin with initiation of respiration [12].
Further studies showed that crSO2 is less affected by mode
of delivery (e.g., vaginal delivery versus cesarean section)
[13–15] than SpO2 and HR. Lower SpO2 and HR values
have been reported in infants born via cesarean section
compared with infants born vaginally [14]. The different
behavior of crSO2 and SpO2 might be due to changes/de-
creases in cerebral blood flow (CBF) [16]. Differences in
arterial oxygen content of the blood or shunting through
the patent ductus arteriosus (or both) are most likely the
reason for CBF changes/differences [16, 17]. In addition,
there is increasing evidence that cerebral tissue oxygen-
ation can be modified by resuscitation interventions in
preterm infants [18–21]. It has been demonstrated that
preterm infants who need respiratory support showed sig-
nificantly lower crSO2 values compared with those who
do not [19].
Therefore, as the brain is the most vulnerable organ of
the infant, to monitor cerebral oxygenation in a
non-invasive way is a potentially useful to guide supple-
mental oxygen and respiratory support in neonates. In a
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two-center prospective observational case control study,
we demonstrated that neonates developing an intra-ven-
tricular hemorrhage (IVH) during the first week after
birth showed lower crSO2 values already during immedi-
ate transition compared with neonates without IVH [22].
COSGOD phase I/II trial
Based on the findings in the observational studies [18–
22], preterm neonates of less than 34 weeks of gestation
were enrolled in a prospective randomized controlled
pilot feasibility study at two tertiary-level neonatal inten-
sive care units (Graz, Austria and Edmonton, Canada)
[23]. In an NIRS-visible group, crSO2 monitoring in
addition to routine monitoring with pulse oximetry and
ECG was used to guide respiratory and supplemental
oxygen support during the first 15 min after birth. In the
NIRS-not-visible group, routine monitoring which con-
sisted of pulse oximetry and ECG was used. The primary
outcomes were burden of cerebral hypoxia (<10th cen-
tile) or hyperoxia (>90th centile) measured in percentage
minutes crSO2 during the first 15 min after birth. In the
NIRS-visible group, the burden of cerebral hypoxia was
halved with a relative reduction of 55.4% (95% confi-
dence interval 37.6–73.2%; P = 0.028) [22].
Assessment of brain injury
Cerebral ultrasonography is a valuable screening tool to
determine significant brain injury like IVH grade 1–3 (+
periventricular hemorrhage), cerebellar hemorrhage, and
periventricular leukomalacia (PVL) grade 1–3 when con-
ducted regularly over the first weeks of life in preterm in-
fants [24]. Magnetic resonance imaging (MRI) scans of
the brain offer even more precise information [25, 26].
However, ultrasound abnormalities in low-gestational-age
neonates are already strongly associated with impaired
psychomotor and mental development. Children without
cranial ultrasound abnormality had the lowest probability
of delayed psychomotor or mental development [27].
Trial objectives
Based on the findings in the observational studies and
COSGOD phase I/II trial, the objective of the present
clinical trial is to monitor crSO2 using NIRS INVOS
5100 (Medtronic, Minneapolis, MN, USA) in addition to
routine monitoring of SpO2 and HR to guide supple-
mental oxygen delivery and respiratory/circulatory sup-
port in preterm neonates during the first 15 min after
birth.
The primary aim is to increase survival without
cerebral injury at discharge or term age. The second-
ary aim is to assess neonatal morbidity until discharge
or term age.
We hypothesize that supplemental oxygen support
and respiratory/circulatory support guided by crSO2 and
SpO2/HR monitoring during the first 15 min after birth
will increase survival without cerebral injury and reduce
morbidities in preterm neonates of less than 32 weeks of
gestation.
Methods
Design
The present trial is an investigator-initiated, randomized,
multi-center, multi-national, clinical trial that will enroll
362 preterm neonates of less than 32 weeks of gestation
in the study group and 362 preterm neonates of less
than 32 weeks of gestation in the control group (Figs. 1
and 2). The trial is carried out in accordance with the
Declaration of Helsinki in its latest form and the “Inter-
national Conference of Harmonization – Good Clinical
Practice” (ICH GCP) guidelines.
Patients
Preterm neonates of less than 32 weeks of gestation are
eligible for the study. Further inclusion criteria are the
decision to provide full life support, written informed
consent, and the application of NIRS sensors within 3
min after birth. Exclusion criteria are decision not to
provide full life support, no written informed consent, or
severe congenital malformation of brain, heart, lung, or
prenatal cerebral injury or a combination of these.
Sample size and statistical analyses
According to data of two European centers (Medical
University of Graz and Erasmus Medical Center in Rot-
terdam) and one Canadian center (Royal Alexandra Hos-
pital in Edmonton), the percentage of neonates who
survive without cerebral injury ranges from 56% to 77%
and the overall percentage is 65%. Given an increase of
neonates who survive without cerebral injury from 65%
to 75%, 329 neonates in each group are required to de-
tect this difference with a two-group chi-squared test
with a 0.05 two-sided significance level and a power of
80%. Given a dropout rate of 10%, a total of 724 neo-
nates will be enrolled.
Demographic and baseline data for the infants will be
compared between groups (study group versus control
group) using the chi-squared test or Fisher’s exact test in
the case of categorical variables and using the t test or
Mann–Whitney U test in the case of continuous vari-
ables. To investigate the primary hypothesis whether the
frequency of cerebral injury in preterm neonates of less
than 32 weeks of gestation will be different in the two
groups, a chi-squared test will be performed. Secondary
outcome parameters including mortality and neonatal
morbidities (cerebral injury, culture-proven early-onset
infection/sepsis, necrotizing enterocolitis, bronchopul-
monary dysplasia, retinopathy of prematurity, and per-
sistent ductus arteriosus receiving intervention) will be
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compared between groups by using the chi-squared test
or Fisher’s exact test. Exploratory outcomes (need for re-
spiratory support, intubation, and medications during
resuscitation, need for mechanical ventilation and treat-
ment with catecholamines on the first day after birth)
will be compared between groups by using the
chi-squared test or Fisher’s exact test; trends of monitor-
ing parameters (SpO2, HR, and NIRS parameters) during
the first 15 min after birth will be analyzed by using lin-
ear mixed models. With these linear mixed models, dif-
ferences in the course of the monitored parameters
between groups (study group versus control group) will
be analyzed. Baseline characteristics, which will show
significant differences between groups, will also be in-
cluded in the linear mixed models.
Randomization
Neonates will be randomly assigned before birth to ei-
ther the study group or the control group by using the
web-based randomization service (“Randomizer for Clin-
ical Trials”), developed at the Institute for Medical In-
formatics, Statistics and Documentation, Medical
University of Graz (https://www.randomizer.at/random/
). The ratio of allocation is 1:1. Patients will be stratified
Fig. 1 Trial flow chart. Abbreviations: ECG electrocardiogram, ITT intention-to-treat, NIRS near-infrared spectroscopy
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according to trial site. In case of multiple births, only
the first infant will be randomly assigned.
Informed consent procedure
Parents of potential participants will be invited to enroll
their preterm neonates before delivery or, if permitted
by local regulations, after delivery and resuscitation (de-
ferred consent).
Groups
In the study group, supplemental oxygen support and
respiratory/circulatory support are guided by crSO2
and SpO2/HR monitoring. In the control group, sup-
plemental oxygen support and respiratory/circulatory
support are guided by SpO2/HR monitoring according
routine resuscitation management; the resuscitation
team is blinded to the crSO2 monitoring.
Duration of interventions
Monitoring and clinical interventions start within 3 min
after birth and last for 15 min after birth.
Duration of follow-up
Each neonate will be followed until discharge or until
term date (37–42 weeks of gestation).
Cerebral ultrasound will be performed at 2–24 h (op-
tional), 2–5 days, 6–8 days, 12–16 days, before dis-
charge/37–42 weeks of gestation and MRI (optional)
before discharge, or at 37–42 weeks of gestation.
Monitoring
The antepartum medical history and birth history will be
collected. Gestational age, birth weight, gender, pH of
umbilical artery, and Apgar score will be documented
for each neonate. Continuous positive airway pressure
and positive pressure ventilation with a face mask, if ne-
cessary, will be performed.
Monitoring during the first 15 min after birth consists
of (i) pulse oximetry for SpO2 and HR as routine
non-invasive monitoring, (ii) ECG for HR as routine
non-invasive monitoring, and (iii) NIRS measurements.
NIRS measurements will be blinded in the control
group.
For NIRS measurements, the Invos™ Cerebral/Somatic
Oximeter monitor (Medtronic) with the neonatal sensor
will be used.
Immediately after birth, when the neonate is brought
to the resuscitation area, the cerebral NIRS sensor will
be placed on the left forehead and fixed with a continu-
ous positive airway pressure cap or elastic bandage on
the left forehead. ECG electrodes will be applied to the
chest for HR monitoring. One pulse-oximetry sensor will
be applied to the right palm or wrist for monitoring
pre-ductal SpO2 and HR.
Interventions
Resuscitation will be conducted in accordance with the
“Consensus Guidelines” on the management of neonatal
respiratory distress syndrome [28, 29], but cerebral oxy-
gen saturation targeting and resuscitation will be at the
discretion of the clinical team.
Control group
Depending on the infants’ breathing efforts and HR, the
SpO2 targeting is conducted in accordance with “Local
Guidelines” and “Resuscitation Guidelines” [28, 29] but
at least between the 10th and 90th centiles [30] (Fig. 3).
If SpO2 remains less than the 10th centile or below the
local lower limit, respiratory support will be increased/
started or fraction of inspired oxygen (FiO2) will be
Fig. 2 Schedule of enrolment, intervention and assessments. Abbreviations: MRI magnetic resonance imaging, NIRS near-infrared spectroscopy
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increased by 10–20% every 60 s. Respiratory support will
be reduced/stopped or FiO2 will be reduced by 10–20%
if SpO2 remains stable more than the 10th centile [30]
or above the local lower limit for more than 60 s or if
SpO2 is more than the 90th centile [30] or above the
local upper limit. The clinical team will be blinded to
the crSO2 monitoring.
Study group
In the study group, the crSO2 monitoring is visible to
the clinical team (Fig. 4). If SpO2 is within local limits
and at least between the 10th and 90th centiles, the
crSO2 value will be considered. If crSO2 is less than the
10th centile (Fig. 5) [31], respiratory support will be
started or increased or oxygen support will be increased
every 60 s by 10–20%. In case of history of volume loss
and clinical signs of volume loss, an administration of
intravenous fluid (10 mL/kg) can be considered [28, 29].
Respiratory support will be reduced/stopped or FiO2 will
be reduced by 10–20% if crSO2 remains stable more
than the 10th centile [31] for more than 60 s or if crSO2
is more than the 90th centile [31].
Outcome measure
The primary outcome measure is survival without cere-
bral injury defined as any grade of IVH or cystic PVL.
The secondary outcome measures include mortality and
neonatal morbidities (cerebral injury, culture-proven
early-onset infection/sepsis, necrotizing enterocolitis,
bronchopulmonary dysplasia, retinopathy of prematurity,
and persistent ductus arteriosus receiving intervention).
The exploratory outcome measures are need for respira-
tory support, intubation, and medications during resus-
citation; need for mechanical ventilation and treatment
with catecholamines on the first day after birth; and
monitoring parameters (SpO2, HR, and NIRS parame-
ters) during the first 15 min after birth.
Outcome assessment tools
All-cause mortality will be recorded. Cerebral injury will
be assessed by cerebral ultrasound at 2–24 h (optional),
2–5 days, 6–8 days, 12–16 days, before discharge/37–42
weeks and optionally cerebral injury will be assessed by
cerebral MRI, if performed routinely—mainly without
sedation during postprandial sleep—before discharge or
term age (37–42 weeks of gestation). Case history will be
assessed until discharge or term age, depending on what
comes first.
Blinding
Owing to the nature of the trial, the intervention cannot
be blinded for the clinical staff and the parents. How-
ever, blinding will be used in some other aspect of the
trial. The allocation sequence will be concealed.
Data management
Source data will be registered in the participant’s medical
records/case report form (CRF) and the electronic CRF
(eCRF). A common web-based eCRF will be used and
entered in a central database (Medical Informatics,
Fig. 3 Intervention - Control group. Abbreviations: CPAP continuous positive airway pressure, FiO2 fraction of inspired oxygen, HR heart rate, IPPV
intermittent positive-pressure ventilation, SpO2 arterial oxygen saturation
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Statistics and Documentation, Medical University of
Graz). Data entry into the central database is the respon-
sibility of the investigators. After establishment of a
“clean file”, the database will be locked, and data will be
stored for statistical analysis at the Institute for Medical
Informatics, Statistics and Documentation, Medical Uni-
versity of Graz.
Trial data will be handled in accordance with regula-
tions of the data protection agency in the respective
countries. After completion of statistical data analysis,
data will be pseudo-anonymized and deposited at the
Medical University of Graz. After the end of trial, the
data will be archived for 15 years in accordance with
GCP guidelines. At each trial site, the data flow will be
monitored in accordance with the GCP principles by a
locally appointed external monitoring committee.
Safety
The preterm patient population is a very vulnerable and
often seriously ill group. Most adverse events may be of
a serious nature with or without the COSGOD trial
intervention, and both groups are expected to have a
very high proportion of serious adverse events (SAEs). It
is therefore not possible, or meaningful, to record and
Fig. 4 Intervention - Study group. Abbreviations: CPAP continuous positive airway pressure, FiO2 fraction of inspired oxygen, HR heart rate, IPPV
intermittent positive-pressure ventilation, SpO2 arterial oxygen saturation
Fig. 5 10th and 90th centiles of cerebral tissue oxygen saturation (crSO2) in each minute after birth (according to Table 1 “All neonates”
published in Pichler et al. [31])
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report all adverse events. The SAE to be reported is
mortality. Serious adverse reaction and suspected unex-
pected serious adverse reactions (SUSARs) will be re-
ported to ethic committees and authorities.
An independent safety committee will perform a first
monitoring after the inclusion of 20% of the neonates to
evaluate the risk of SAEs and efficacy (primary and sec-
ondary outcome parameters) of the intervention with
“certain” or “probably/likely” relationship with the cere-
bral NIRS oximeter or the application of the treatment
guideline. The participants will be insured in accordance
with existing legislation of their respective country.
Ethical considerations
The COSGOD trial will start at the different centers ran-
domly assigning participants after approvals from the
relevant ethics committees and authorities have been re-
ceived. All parents will receive written and oral informa-
tion about the trial before they are asked for their
written consent. They will enroll their newborn infant in
the trial only by their own free will and can withdraw
their consent for participation at any time. If a parent
wishes to withdraw the consent for participation, the pa-
tient will receive treatment in accordance with the re-
spective hospital’s standard procedures. The trial will be
conducted in compliance with the guidelines of the Dec-
laration of Helsinki in its latest form and the ICH GCP
guidelines.
In case of modifications in the study protocol that are
not merely of a formal nature but contain changes per-
tinent to the study participants, a renewed vote of the
ethics committee will be obtained. If applicable, the pa-
tients/parents will be informed in the patient informa-
tion and consent form about changes in the terms and
conditions of the trial.
Discussion
The primary aim of the present clinical trial is to in-
crease survival without cerebral injury in preterm neo-
nates by monitoring crSO2 in addition to routine
monitoring of SpO2 and HR to guide supplemental oxy-
gen delivery, respiratory support, or circulatory support
(fluid bolus) (or a combination of these) in preterm neo-
nates during the first 15 min after birth. In the pilot
study [23], we demonstrated feasibility of NIRS measure-
ments even in extremely-low-birth-weight infants. Bur-
den of cerebral hypoxia was reduced without any
SUSARs; in addition, a trend toward reduction of cere-
bral injury was observed. The SafeBoosC phase II ran-
domized clinical trial recently demonstrated that the
combination of crSO2 measurement and a treatment
guideline could reduce the burden of cerebral hypoxia in
preterm neonates with less than 28 weeks of gestation
during the first three days after birth [32]. In this study,
a trend toward reduction of cerebral injury was also ob-
served. Both, COSGOD phase I/II and SafeBoosC phase
II had trends to lower mortality or cerebral injury (or
both), suggesting a positive effect on short-term out-
come; however, neither study was powered for cerebral
injury [23, 32].
Since pulse oximetry and ECG are recommended dur-
ing immediate transition and resuscitation when moni-
toring is performed [28, 29], both monitoring methods
will be performed in all neonates. SpO2 will be kept
within recommended/local limits in all neonates (at least
between the 10th and 90th centiles of published refer-
ence ranges) [30]. Therefore, in the study group and in
the control group, hypoxia defined as SpO2 below the
lower limit and hyperoxia defined as SpO2 above the
upper limit should be avoided.
Monitoring of crSO2 would suggest increased respira-
tory support and increased use of supplemental oxygen
in case of low cerebral oxygenation. In the COSGOD
phase I/II trial, the supplemental oxygen support was
lower in the NIRS-visible group in the first minutes [23].
For COSGOD III, according to ICH GCP, the research
and clinical team involved in conducting this trial should
be qualified by education, training, and experience to
perform NIRS measurements and interventions.
Owing to the short intervention period, irritation of
the skin caused by NIRS sensors will be unlikely. More-
over, this has not been observed in other studies using
NIRS during immediate transition [2, 11]. Risks related
to the manipulation of the patient during positioning
and re-positioning of the NIRS sensors will be mini-
mized by experience in use of NIRS. Neonates will al-
ways be continuously monitored and observed by the
resuscitation team.
In conclusion, additional monitoring of crSO2 and
dedicated interventions are feasible during immediate
transition and resuscitation and reduce the burden of
cerebral hypoxia. The present trial will examine whether
monitoring of crSO2 and dedicated interventions will
improve survival without cerebral injury.
Trial status
Recruitment started in September 2018 and is expected
to be completed at the end of 2020.
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